class = “cf”>
According to a study published in the journal The Lancet Infectious Diseases, the two-dose vaccine from Johnson & Johnson was declared to be both safe and well tolerated.
IMMUNITY LASTS FOR 2 YEARS … 98 PERCENT EFFECTIVE
The EBOVAC-Salone trial is the first to test the vaccine in an area affected by the 2014-16 Ebola outbreak, the worst on record. He is also the first to test the vaccine on children. Children under five were particularly at higher risk of death. About 98% of the trial participants exhibited antibody responses 21 days after the second dose of vaccine, and the immune response lasted for at least two years in adults.
The two-stage trial took place between September 2015 and July 2018. The safety and ability of the vaccine to elicit an immune response was examined in the initial phase, when 43 adults received the Ad26.ZEBOV vaccine, followed of the MVA-BN-Filo vaccine 56 days later. was administered two years after the first dose. A strong immune response then occurred within seven days. In the second phase, 400 adults and 576 children were vaccinated either with the Ebola vaccination schedule or with a single dose of meningococcal vaccine followed by placebo on day 57.
IT WILL SAVE MANY YOUNG LIVES
class = “cf”>
The first author of the pediatric article, assistant professor at LSHTM, Dr Muhammed Afolabi, said:
This work represents a significant advance in the development of a vaccine against Ebola virus disease for children. It also contributes to the public health response to Ebola outbreaks.
This study, with contributions from Sierra Leonean scientists and local communities, is the first published study to evaluate a two-dose vaccination schedule in children in a randomized controlled trial. The results show that this vaccine regimen has the potential to save many young lives.
THE EBOLA DISEASE CERTAINLY NOT ELIMINATED
Professor Deborah Watson-Jones, LSHTM, said: “Future Ebola virus outbreaks pose a real threat. It is important to remember that this disease will not go away. We must not slow down efforts to contain it quickly. Vaccines are essential to achieve both of these goals. ”Used his statements.
The vaccine received market clearance from the European Commission in July 2020. Johnson & Johnson said more than 250,000 people who have participated in clinical trials and vaccination initiatives have received at least the first dose, 200,000 of whom were fully vaccinated.
class = “cf”>
Ebola is spread between people by contact with the blood or body fluids of an infected person, or by contact with objects contaminated with these fluids. Anyone caring for an Ebola patient and performing funeral rites involving direct contact with the body of the deceased falls into the high risk category. According to the World Health Organization, the death rate from Ebola has ranged from 25 to 90% in past epidemics.
This guide guides gastronomy enthusiasts